Standout Papers

Lung cancer: current therapies and new targeted treatments 2011 2026 2016 2021 2.4k
  1. Lung cancer: current therapies and new targeted treatments (2016)
    Fred R. Hirsch, Giorgio V. Scagliotti et al. The Lancet
  2. Current Challenges in Cancer Treatment (2016)
    Jon Zugazagoitia, Santiago Ponce et al. Clinical Therapeutics
  3. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (2018)
    David Westover, J. Zugazagoitia et al. Annals of Oncology
  4. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study (2011)
    Robert Pirker, Jose R. Pereira et al. The Lancet Oncology
  5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial (2012)
    Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology
  6. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer (2013)
    Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology
  7. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 (2020)
    Luis Paz‐Ares, David Vicente et al. Journal of Thoracic Oncology
  8. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial (2017)
    Luis Paz‐Ares, E.H. Tan et al. Annals of Oncology
  9. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019)
    Jhanelle E. Gray, Augusto Villegas et al. Journal of Thoracic Oncology
  10. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023)
    Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology
  11. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial (2022)
    Vivek Subbiah, Philippe A. Cassier et al. Nature Medicine
  12. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC (2023)
    Itziar Otano, Álvaro C. Ucero et al. Nature Reviews Clinical Oncology
  13. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer (2023)
    Charles M. Rudin, Martin Reck et al. Journal of Hematology & Oncology
  14. New promises and challenges in the treatment of advanced non-small-cell lung cancer (2024)
    Luis Paz‐Ares, Federico Cappuzzo et al. The Lancet
  15. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial (2024)
    Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 6 from Science/Nature 76 standout
Sub-graph 1 of 16

Citing Papers

Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy
2024 Standout
Fluorescent Probes for Disease Diagnosis
2024 Standout

Works of Luis Paz‐Ares being referenced

Lung cancer: current therapies and new targeted treatments
2016 Standout
Inhibition of HSP90 molecular chaperones: moving into the clinic
2013

Author Peers

Author Last Decade Papers Cites
Luis Paz‐Ares 12823 11087 7419 681 22.1k
Kenneth J. O’Byrne 12402 10276 8206 586 23.0k
Suresh S. Ramalingam 15160 14115 8642 584 24.7k
Giampaolo Tortora 13500 7644 9748 619 23.7k
Byoung Chul Cho 12760 12497 5501 672 19.0k
Mark A. Socinski 15354 14798 4880 516 22.4k
Yoshitaka Fujii 8242 8943 7574 436 19.6k
D. Ross Camidge 14715 16480 8384 533 23.6k
David R. Spigel 14076 9703 4947 603 19.4k
Rafael Rosell 14871 16187 9816 541 26.1k
Keunchil Park 17565 16632 6064 564 26.7k

All Works

Loading papers...

Rankless by CCL
2026